Keliximab Biosimilar – Anti-CD4 mAb – Research Grade

Description of Keliximab Biosimilar - Anti-CD4 mAb - Research Grade

Keliximab Biosimilar – Anti-CD4 mAb – Research Grade: A Promising Antibody for Targeting CD4 in Therapeutic Applications Keliximab Biosimilar, also known as Anti-CD4 monoclonal antibody (mAb), is a research grade antibody that targets CD4, a cell surface protein found on T helper cells. This biosimilar is a promising therapeutic tool for various diseases, as it has the potential to modulate the immune response and treat a variety of disorders.

Structure of Keliximab Biosimilar

Keliximab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL) and one variable domain (VL).

The variable domains of Keliximab Biosimilar are responsible for its specificity and binding to CD4. The constant domains, on the other hand, play a crucial role in mediating effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Keliximab Biosimilar

Keliximab Biosimilar binds specifically to CD4, which is expressed on the surface of T helper cells. This binding inhibits the interaction between CD4 and major histocompatibility complex (MHC) class II molecules, leading to the suppression of T cell activation and proliferation.

CD4 is a co-receptor for the T cell receptor (TCR) and plays a critical role in the immune response. It is involved in the recognition of antigens presented by antigen-presenting cells (APCs) and the activation of T helper cells. By targeting CD4, Keliximab Biosimilar can modulate the immune response and potentially treat various diseases.

In addition to its inhibitory effect on T cell activation, Keliximab Biosimilar also has the ability to induce apoptosis in CD4+ T cells. This mechanism of action makes it a potential therapeutic tool for diseases characterized by excessive T cell proliferation, such as autoimmune disorders and certain types of cancer.

Application of Keliximab Biosimilar

Due to its specific targeting of CD4, Keliximab Biosimilar has a wide range of potential applications in therapeutic settings. Some of the diseases that could potentially benefit from this biosimilar include:

• Autoimmune diseases: Keliximab Biosimilar has shown promising results in preclinical studies for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. By inhibiting T cell activation and inducing apoptosis, it can help reduce inflammation and control the progression of these diseases.
• Organ transplant rejection: CD4+ T cells play a crucial role in the rejection of transplanted organs. Keliximab Biosimilar can potentially be used as an immunosuppressive therapy to prevent organ rejection by targeting and suppressing these cells.
• Cancer: CD4+ T cells are also involved in the development and progression of certain types of cancer. By inducing apoptosis in these cells, Keliximab Biosimilar could potentially be used as a targeted therapy for cancer treatment.
• HIV/AIDS: CD4 is the primary receptor for the human immunodeficiency virus (HIV). By blocking the interaction between CD4 and HIV, Keliximab Biosimilar can potentially inhibit viral entry and replication, making it a potential treatment for HIV/AIDS.

In addition to its therapeutic applications, Keliximab Biosimilar can also be used as a research tool for studying the role of CD4 in various diseases and for developing new therapies targeting